ID   ANBL-6-luc
AC   CVCL_B7F5
DR   cancercelllines; CVCL_B7F5
DR   Wikidata; Q112929238
RX   PubMed=32123307;
CC   Population: Caucasian.
CC   Characteristics: Produces Ig lambda.
CC   Characteristics: IL6 dependent.
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Ter (c.991C>T); ClinVar=VCV000922893; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Tyr425Thrfs*36 (c.1272delC); Zygosity=Homozygous (from parent cell line).
CC   Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P08659; Firefly luciferase (Note=With optimized codon usage for mammalian expression = effLuc).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: B-cell; CL=CL_0000236.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_5425 ! ANBL-6
SX   Female
AG   67Y
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 10-09-24; Version: 6
//
RX   PubMed=32123307; DOI=10.1038/s41375-020-0785-1; PMCID=PMC7483300;
RA   Sarin V., Yu K., Ferguson I.D., Gugliemini O., Nix M.A., Hann B.,
RA   Sirota M., Wiita A.P.;
RT   "Evaluating the efficacy of multiple myeloma cell lines as models for
RT   patient tumors via transcriptomic correlation analysis.";
RL   Leukemia 34:2754-2765(2020).
//